Discover open access scientific publications

Search, annotate, share and cite publications

Publications by I. Fughhi

P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated With Immunotherapy and Ramucirumab Plus Docetaxel.

Journal of Thoracic Oncology

English

P2.01-61 Body Mass Index Over Time Is Associated With Overall Survival in Advanced NSCLC Patients Treated With Immunotherapy.

Journal of Thoracic Oncology

English

Related publications

P2.01-112 Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients With Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology

English

Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients With NSCLC

Materia Socio Medica

2016

English

Prognostic Value of Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio for Renal Outcomes in Patients With Rapidly Progressive Glomerulonephritis

Journal of Clinical Medicine

2020

English

Prognostic Role of Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio in Patients With Bone Metastases

British Journal of Cancer

Cancer Research

Oncology

2018

English

The Prognostic Impact of Neutrophil-To-Lymphocyte Ratio, Lymphocyte-To-Monocyte Ratio, and Platelet-To-Lymphocyte Ratio in Patients With Advanced Colorectal Cancer Treated With First-Line Chemotherapy

Przeglad Gastroenterologiczny

Gastroenterology

2018

English

P1.01-34 Docetaxel Plus Ramucirumab With Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

Journal of Thoracic Oncology

English

Prognostic Value of Neutrophil‐to‐lymphocyte Ratio and Platelet‐to‐lymphocyte Ratio for Breast Cancer Patients: An Updated Meta‐analysis of 17079 Individuals

English

P2.17-25 Post-Treatment Neutrophil to Lymphocyte Ratio in Locally Advanced NSCLC Patients Treated With Concurrent Chemoradiotherapy

Journal of Thoracic Oncology

English

Prognostic Value of Lymphocyte/Monocyte Ratio and Neutrophil/Lymphocyte Ratio at Diagnosis of Follicular Lymphoma.

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by I. Fughhi

P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated With Immunotherapy and Ramucirumab Plus Docetaxel.

P2.01-61 Body Mass Index Over Time Is Associated With Overall Survival in Advanced NSCLC Patients Treated With Immunotherapy.

Related publications

P2.01-112 Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients With Lung Cancer Treated With Nivolumab

Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients With NSCLC

Prognostic Value of Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio for Renal Outcomes in Patients With Rapidly Progressive Glomerulonephritis

Prognostic Role of Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio in Patients With Bone Metastases

The Prognostic Impact of Neutrophil-To-Lymphocyte Ratio, Lymphocyte-To-Monocyte Ratio, and Platelet-To-Lymphocyte Ratio in Patients With Advanced Colorectal Cancer Treated With First-Line Chemotherapy

P1.01-34 Docetaxel Plus Ramucirumab With Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

Prognostic Value of Neutrophil‐to‐lymphocyte Ratio and Platelet‐to‐lymphocyte Ratio for Breast Cancer Patients: An Updated Meta‐analysis of 17079 Individuals

P2.17-25 Post-Treatment Neutrophil to Lymphocyte Ratio in Locally Advanced NSCLC Patients Treated With Concurrent Chemoradiotherapy

Prognostic Value of Lymphocyte/Monocyte Ratio and Neutrophil/Lymphocyte Ratio at Diagnosis of Follicular Lymphoma.